Edouard Ngendahayo1, Alex Bonane, Georges Ntakiyiruta, Aline Munyanshongore, Narcisse Muganga, Joel Bikoroti, Jason M Mwenda, Jacqueline E Tate, Fidele Ngabo. 1. From the *Department of Surgery, King Faisal Hospital; †Department of Surgery, University Teaching Hospital of Kigali; ‡Kacyiru Police Hospital; §Department of Pediatrics, University Teaching Hospital of Kigali; ¶Department of Surgery, University Teaching Hospital of Butare, Kigali, Rwanda; ‖World Health Organization, Regional Office for Africa (WHO/AFRO), Brazzaville, Republic of Congo; **Centers for Disease Control and Prevention, Atlanta, GA; and ††Maternal and Child Health Unit, Ministry of Health, Kigali, Rwanda.
Abstract
BACKGROUND: In some settings, rotavirus vaccines have been associated with a small risk of intussusception. This study describes the demographics, clinical characteristics and outcomes of children with intussusception in Rwanda before vaccine introduction in May 2012. METHODS: We retrospectively reviewed data on pediatric patients treated for intussusception at University Teaching Hospital of Kigali from January 2009 to June 2012. Hospital registries were reviewed to identify intussusception cases. Archived patient files were abstracted to collect data on demographics, clinical presentation, surgery and outcome. RESULTS: During the study period, 70 children ≤19 years of age were treated for intussusception and patient files were retrieved for 60 (86%) cases. Over half of patients (58%) were <1 year of age and 90% were transferred from a district hospital. Only 30% of patients presented within 3 days of symptom onset and 35% experienced a delay of ≥6 hours between surgical review and surgery. Surgical complications were experienced by 35% of children. Over 1 quarter (28%) of children died. Compared with children who survived, children who died were significantly more likely to have experienced complications (21% vs. 71%; P < 0.001) and to be female (28% vs. 65%; P = 0.009). DISCUSSION: Mortality due to intussusception was high among Rwanda children. Delays in presentation and treatment were common. Assessing trends in the number of cases to monitor for vaccine-associated intussusception will be difficult. Additional work is needed to further understand risk factors for mortality, to calculate incidence rates and to monitor the safety of the rotavirus vaccination program.
BACKGROUND: In some settings, rotavirus vaccines have been associated with a small risk of intussusception. This study describes the demographics, clinical characteristics and outcomes of children with intussusception in Rwanda before vaccine introduction in May 2012. METHODS: We retrospectively reviewed data on pediatric patients treated for intussusception at University Teaching Hospital of Kigali from January 2009 to June 2012. Hospital registries were reviewed to identify intussusception cases. Archived patient files were abstracted to collect data on demographics, clinical presentation, surgery and outcome. RESULTS: During the study period, 70 children ≤19 years of age were treated for intussusception and patient files were retrieved for 60 (86%) cases. Over half of patients (58%) were <1 year of age and 90% were transferred from a district hospital. Only 30% of patients presented within 3 days of symptom onset and 35% experienced a delay of ≥6 hours between surgical review and surgery. Surgical complications were experienced by 35% of children. Over 1 quarter (28%) of children died. Compared with children who survived, children who died were significantly more likely to have experienced complications (21% vs. 71%; P < 0.001) and to be female (28% vs. 65%; P = 0.009). DISCUSSION: Mortality due to intussusception was high among Rwanda children. Delays in presentation and treatment were common. Assessing trends in the number of cases to monitor for vaccine-associated intussusception will be difficult. Additional work is needed to further understand risk factors for mortality, to calculate incidence rates and to monitor the safety of the rotavirus vaccination program.
Authors: Richard Omore; Francis Osawa; Janet Musia; Brian Rha; Amina Ismail; Nicholas Mukaria Kiulia; Fenny Moke; John Vulule; Anthony Mungai Wainaina; John Tole; Stanley Mugambi Machoki; J Pekka Nuorti; Robert F Breiman; Umesh D Parashar; Joel M Montgomery; Jacqueline E Tate Journal: J Pediatric Infect Dis Soc Date: 2015-08-25 Impact factor: 3.164
Authors: Syed M Satter; Negar Aliabadi; Catherine Yen; Paul A Gastañaduy; Makhdum Ahmed; Abdullah Mamun; Khaleda Islam; Meerjady S Flora; Mahmudur Rahman; K Zaman; Mustafizur Rahman; James D Heffelfinger; Stephen P Luby; Emily S Gurley; Umesh D Parashar Journal: Vaccine Date: 2017-09-20 Impact factor: 3.641
Authors: Marie Josée Mukagendaneza; Emmanuel Munyaneza; Esperance Muhawenayo; Dancilla Nyirasebura; Egide Abahuje; John Nyirigira; Jean De Dieu Harelimana; Thierry Zawadi Muvunyi; Florence Masaisa; Jean Claude Byiringiro; Théobald Hategekimana; Claude Mambo Muvunyi Journal: Patient Saf Surg Date: 2019-02-18
Authors: Evans Mwila Mpabalwani; Bruce Bvulani; Julia Simwaka; Pearson Chitambala; Belem Matapo; Jacqueline Tate; Umesh Parashar; Jason Mwenda Journal: Pan Afr Med J Date: 2021-07-28
Authors: Tapsoba Wendlamita Toussaint; Albert Wandaogo; Idrissa Clétus Yaméogo W; Isso Ouédraogo; Somkièta Modeste Francis Ouédraogo; Olivier Zampou; Bernadette Béré; Negar Aliabadi; Eyal Leshem; Moumouni Nikièma; Ma Ouattara; Jason M Mwenda; Isidore Bonkoungou; Emile Bandré; Umesh D Parashar; Jacqueline E Tate Journal: Pan Afr Med J Date: 2021-07-28